Clinic Roundup
GenSpera Inc., of San Antonio, said UK regulators cleared the firm for a Phase II trial of G-202 in prostate cancer patients who have failed prior hormonal therapy. The study is expected to enroll up to 40 patients with chemotherapy-naïve, metastatic castrate-resistant disease.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Our address has changed:
BioWorld | 115 Perimeter Center Place
Suite: 1100 | Atlanta, Georgia 30346, USA
Suite: 1100 | Atlanta, Georgia 30346, USA
For Sales Inquiries, please contact Tyler Beatty:
In the U.S. and Canada: 1-855-260-5607
Outside the U.S.: 1-646-822-4549
tyler.beatty@thomsonreuters.com
In the U.S. and Canada: 1-855-260-5607
Outside the U.S.: 1-646-822-4549
tyler.beatty@thomsonreuters.com
Part of Thomson Reuters
Note: our contact information has changed
Customer Service:
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
BioWorld.support@thomsonreuters.com
Hours: Monday - Friday, 8:00am - 6:00 pm EST
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
BioWorld.support@thomsonreuters.com
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2014 Thomson Reuters. Reproduction, reposting content is strictly prohibited.
Free Ezine
Sign up for Highlights FREE e-mail newsletter